Saikosaponin D

製品コードS5454 バッチS545401

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₄₂H₆₈O₁₃

分子量

780.98

CAS No.

20874-52-6

Solubility (25°C)*

体外

DMSO

100 mg/mL (128.04 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Clear solution

5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O

2.5mg/ml

Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Saikosaponin D, a calcium mobilizing agent (SERCA inhibitor), is a type of Saponin derivative, which is a component extracted from Bupleurum falactum. Saikosaponin D has anti-cancer activities.
in vitro	Saikosaponin D is a novel autophagic inducer that induces autophagy in various types of cancer cells through the formation of autophagosomes as measured by GFP-LC3 puncta formation. Saikosaponin D increases cytosolic calciumlevel via direct inhibition of sarcoplasmic/endoplasmic reticulum Ca2+ATPase pump, leading to autophagy induction through the activation of the Ca2+/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mammalian target of rapamycin pathway. Its treatment causes the disruption of calcium homeostasis, which induces endoplasmic reticulum stress as well as the unfolded protein responses pathway^[1]. Ssd can exhibit anti-cancer activities, which is mediated by the induction of apoptosis and autophagic cell death regardless of p53 status. Low dose Ssd is capable of sensitizing chremosensitive or chemoresistant lung and cervical cancer or hepatoma cells to anti-cancer drug- or radiation-induced apoptosis. Ssd also down-regulates PPM1D content, leading to the activation of Chk1, phosphorylation of Cdc25c and Cdk1, and subsequent G2/M arrest and apoptosis^[2].

製品説明

Saikosaponin D, a calcium mobilizing agent (SERCA inhibitor), is a type of Saponin derivative, which is a component extracted from Bupleurum falactum. Saikosaponin D has anti-cancer activities.

in vitro

Saikosaponin D is a novel autophagic inducer that induces autophagy in various types of cancer cells through the formation of autophagosomes as measured by GFP-LC3 puncta formation. Saikosaponin D increases cytosolic calciumlevel via direct inhibition of sarcoplasmic/endoplasmic reticulum Ca2+ATPase pump, leading to autophagy induction through the activation of the Ca2+/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mammalian target of rapamycin pathway. Its treatment causes the disruption of calcium homeostasis, which induces endoplasmic reticulum stress as well as the unfolded protein responses pathway^[1]. Ssd can exhibit anti-cancer activities, which is mediated by the induction of apoptosis and autophagic cell death regardless of p53 status. Low dose Ssd is capable of sensitizing chremosensitive or chemoresistant lung and cervical cancer or hepatoma cells to anti-cancer drug- or radiation-induced apoptosis. Ssd also down-regulates PPM1D content, leading to the activation of Chk1, phosphorylation of Cdc25c and Cdk1, and subsequent G2/M arrest and apoptosis^[2].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	HeLa and MCF-7 cells
	濃度	10 μM
	反応時間	1, 4, 8 and 24 h
	実験の流れ	HeLa and MCF-7 cells were treated with Ssd (10 μM) for the indicated time, whereas rapamycin (100 nM) and thapsigargin (1 μM) were used as positive control. Cell lysates were harvested and analyzed by western blot for ER stress markers.
動物実験	動物モデル	Pathogen-free, BALB/C male mice aged 6-8 weeks old
	投薬量	1, 5, 10 and 20 mg/kg
	投与方法	intramuscularly

参考

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip [ Adv Healthc Mater, 2023, e2300591.]	PubMed: 37162029

Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip [ Adv Healthc Mater, 2023, e2300591.]

PubMed: 37162029

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。